Endocannabinoid pro129Thr FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain

Journal of Clinical Psychopharmacology

Volumn 30, Issue 4, 2010, Pages 441-445

  Monteleone, Palmiero ^a   Milano, Walter ^b   Petrella, Claudio ^b   Canestrelli, Benedetta ^a   Maj, Mario ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b ASL NA 1   (Italy)

Author keywords

antipsychotics; association; endocannabinoids; genes; polymorphisms; weight gain

Indexed keywords

CANNABINOID RECEPTOR; CLOZAPINE; COMPLEMENTARY DNA; ENDOCANNABINOID; FATTY ACID AMIDASE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PROLINE; PROTEIN CNR 1; QUETIAPINE; RISPERIDONE; UNCLASSIFIED DRUG; AMIDASE; CANNABINOID 1 RECEPTOR; FATTY-ACID AMIDE HYDROLASE;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE FREQUENCY; GENOTYPE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOSIS; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; WEIGHT GAIN; ALLELE; CASE CONTROL STUDY; DRUG EFFECTS; GENETICS; METABOLISM; MIDDLE AGED;

ADULT; ALLELES; AMIDOHYDROLASES; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; DNA, COMPLEMENTARY; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, CANNABINOID, CB1; WEIGHT GAIN;

EID: 77955129795     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181e742c5     Document Type: Article

References (28)

1. Monteleone P, Martiadis V, Maj M. Management of schizophrenia with obesity, metabolic, and endocrinological disorders. Psychiatr Clin N Am. 2009;32:775-794.
2. Green AI, Patel JK, Goisman RM, et al. Weight gain from novel AP drugs: need for action. Gen Hosp Psychiatry. 2000;22:224-235.
3. Muller DJ, Kennedy JL. Genetic of AP treatment emergent weight gain in schizophrenia. Pharmacogenomics. 2006;7:863-887.
4. Perusse L, Rankinen T, Zuberi A, et al. The human obesity gene map: the 2004 update. Obes Res. 2005;13:381-490.
5. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab. 2007;18:27-37.
6. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295:761-775.
7. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 2001;410:822-825.
8. Sipe JC, Waalen J, Gerber A, et al. Overweight and obesity associated with a missense polymorphism in fatty acid amide hydrolase (FAAH). Int J Obes. 2005;29:755-759.
9. Monteleone P, Tortorella A, Martiadis V, et al. The cDNA 385C/A missense polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) is associated with overweight/obesity but not with binge eating disorder in overweight/obese women. Psychoneuroendocrinology. 2008;33:546-550.
10. Benzinou M, Chèvre JC, Ward KJ, et al. Endocannabinoid receptor 1 gene variations increase risk for obesity and modulate body mass index in European populations. Hum Mol Genet. 2008;17:1916-1921.
11. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV Axis I DisordersVPatient Ed. (SCID-I/P, Version 2). New York, NY: New York State Psychiatric Institute, Biometrics Research Department; 1995.
12. Allison DB, Mentore JL, Heo M, et al. AP-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156: 1686-1696.
13. First MB, Gibbon M, Spitzer RL, et al. Structured Clinical Interview for Axis I DSM-IV DisordersVNon-Patient EdV(SCID-I/NP, Version 2.0). New York, NY: New York State Psychiatric Institute, Biometrics Research Department; 1996.
14. Schmidt LG, Samochowiec J, Finckh U, et al. Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. Drug Alcohol Depend. 2002;65:221-224.
15. Dixon J. BMDP Statistical Software. Berkeley: University of California Press; 1985.
16. World Health Organization. Obesity: Preventing and Managing the Global Epidemic: Report of a WHO Consultation on Obesity (WHO/NUT/NCD). Geneva: WHO; 1998.
17. Chiang K, Gerber AL, Sipe JC, et al. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet. 2004;13:1-7.
18. Koethe D, Giuffrida A, Schreiber D, et al. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. Br J Psychiatry. 2009;194:371-372.
19. Jensen DP, Andreasen CH, Andersen MK, et al. The functional Pro129Thr variant of the FAAH gene is not associated with various fat accumulation phenotypes in a population-based cohort of 5,801 whites. J Mol Med. 2007;85:445-449.
20. Monteleone P, Matias I, Martiadis V, et al. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology. 2005;30:1216-1221.
21. Matias I, Gonthier MP, Orlando P, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab. 2006;91:3171-3180.
22. Cote M, Matias I, Lemieux I, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes. 2007;31:692-699.
23. Leroy S, Griffon N, Bourdel MC, et al. Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1. Am J Med Genet. 2001;105:749-752.
24. Seifert J, Ossege S, Emrich HM, et al. No association of CNR1 variations with susceptibility to schizophrenia. Neurosci Lett. 2007;426:29-33.
25. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry. 2004;65(suppl 18):47-56.
26. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825-835.
27. Muller TD, Reichwald K, Bronner G, et al. Lack of association of genetic variants in genes of the endocannabinoid system with anorexia nervosa. Child Adolesc Psychiatry Ment Health. 2008;2:33-39.
28. Tiwari AK, Zai CC, Likhodi O, et al. A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with AP-induced weight gain in schizophrenia. Neuropsychopharmacology. 2010;35:1315-1324.